PAK4可化并稳定MYC以促进急性髓性白血病
Ting Xie1,2, Peipei Sun1,2, Hao Huang1,2
1Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, Hubei, China.
Cell insight
|August 27, 2025
概括
在急性髓性白血病 (AML) 中,MYC稳定是由p21激活的激酶4 (PAK4) 驱动的. 通过诱导协同细胞死亡,同时抑制PAK4和MCL-1为AML提供了有前途的向治疗方法.
科学领域:
- 癌症学
- 分子生物学
- 癌症研究
背景情况:
- MYC失调是急性髓性白血病 (AML) 的一个关键因素.
- MYC蛋白的稳定性由翻译后的修改,包括酸化和无处不在调节.
- 之前的研究发现MYC Serine 67 (S67) 酸化对T细胞急性淋巴细胞白血病 (T-ALL) 的致癌活性至关重要.
研究的目的:
- 研究MYC S67酸化在AML中的作用.
- 在AML中识别MYC S67酸化的酶.
- 探索针对AML的治疗策略.
主要方法:
- 在AML细胞系中研究MYC S67酸化.
- 确定了p21激活酶4 (PAK4) 作为催化MYC S67酸化的酶.
- 在联合治疗中使用PAK4抑制剂 (KPT-9274) 和MCL-1抗剂 (S63845).
主要成果:
- 在AML中存在MYC S67酸化,由PAK4介导.
- PAK4直接与MYC结合,化S67,并抑制FBXW7依赖的全方位化,稳定MYC.
- 抑制PAK4会破坏MYC的稳定,并减少AML的扩散,但补偿性MCL-1上调会限制细胞亡.
- 结合PAK4抑制和MCL-1抗作用会诱导AML细胞的协同致死性.
结论:
- PAK4介导的MYC稳定是AML的一个关键机制.
- 向PAK4会破坏MYC的稳定,并抑制AML的生长.
- 使用PAK4抑制剂和MCL-1抗剂的联合治疗显示出对AML的显著治疗潜力.
相关概念视频
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Anaphase Promoting Complex
2.9K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.9K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K


